GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
GRAIL, Inc. Chief Executive Officer Joshua J. Ofman exercised options covering 26,452 common shares at $14 per share on September 21, 2026, and acquired 26,452 common shares. His reported option position following the exercise was 37,032 shares. The option was originally granted on March 6, 2020, and its performance condition was determined to be met on November 1, 2024.
On September 21, 2026, Ofman also sold 61,452 common shares in eight transactions, at reported per-share prices from $92.3152 to $110.0000; seven of the reported prices were weighted averages for multiple sales. The sales were made under a Rule 10b5-1 trading plan adopted on December 2, 2025.
GRAIL, Inc. (GRAL) received a Rule 144 notice from insider Joshua Ofman covering the potential sale of up to 71,452 shares of common stock through Morgan Stanley Smith Barney. The shares have an aggregate market value of $5,771,178.04, while 44,666,234 shares of common stock were outstanding as of September 21, 2026.
GRAIL, Inc. (GRAL) reported that Chief Executive Officer and director Joshua J. Ofman sold 5,000 shares of Common Stock on August 27, 2026 in an open-market or private transaction pursuant to a Rule 10b5-1 trading plan. The weighted average sale price was $85.0196 per share, with individual trades between $85.00 and $85.11. Following this sale, Ofman directly holds 397,271 shares of GRAIL common stock.
GRAIL, Inc. (GRAL) Chief Financial Officer Aaron Freidin reported selling 7,900 shares of common stock on August 27, 2026 in an open-market transaction under a Rule 10b5-1 trading plan. The weighted average sale price was $85.01 per share, with individual trades between $85.00 and $85.11. After this sale, Freidin directly holds 253,083 shares, which include 314 shares acquired through the company’s ESPP on May 14, 2026.
GRAIL, Inc. (GRAL) received a notice that insider Joshua Ofman intends to sell common stock under Rule 144. The notice covers 10,000 shares of common stock, originally acquired as Restricted Stock Units from the issuer on 08/18/2024. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ, with an indicated aggregate market value of approximately $795,900.00. The securities to be sold are reported as held for the account of Joshua Ofman, and no other Rule 144 sales in the past three months are listed.
GRAIL, Inc. (GRAL) is the issuer for a proposed insider resale under Rule 144 by officer Aaron Freidin12,000 shares of common stock of GRAIL, Inc., to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The securities were acquired from the vesting of restricted stock units during the period from February 28, 2026 through April 3, 2026. The aggregate market value referenced for these shares is $955,080.00.
Farallon Capital Management, L.L.C. and affiliated funds report significant ownership in GRAIL, Inc. common stock under a Schedule 13G/A. Acting as investment manager to a group of investment partnerships referred to as the Farallon Funds, Farallon and a group of individual managing members (the Farallon Individual Reporting Persons) report aggregate beneficial ownership of 4,161,584 Shares, representing 9.6% of GRAIL’s outstanding common stock.
The Farallon Funds directly hold 3,590,563 Shares and 571,021 Pre-Funded Common Stock Purchase Warrants, each warrant currently treated as exercisable into one Share for beneficial ownership purposes. These Warrants are subject to a 9.99% Beneficial Ownership Limitation, which the group states does not currently restrict exercise of any Warrants. The Farallon Funds retain the right to receive dividends and sale proceeds on the securities they hold.
State Street Corporation reported passive ownership of GRAIL Inc. common stock. As of June 30, 2026, it beneficially owned 2,385,514 shares of GRAIL, representing 5.6% of the outstanding common stock.
State Street reported no sole voting or dispositive power, with 2,276,740 shares subject to shared voting power and 2,385,514 shares subject to shared dispositive power. The holdings are attributed to investment adviser subsidiaries including SSGA Funds Management, Inc. and various State Street Global Advisors entities.
PRIMECAP Management Co. reports a significant ownership position in GRAIL, Inc. common stock. As of the reported date, PRIMECAP beneficially owned 21,801,016 shares, representing 5.08% of GRAIL’s outstanding common shares.
Within this stake, PRIMECAP has sole power to vote 2,174,440 shares and sole power to dispose of 2,180,106 shares, with no shared voting or dispositive power disclosed. This filing is identified as Amendment No. 3 to a previous ownership report.